MarketInOut Stock Screener Log In | Sign Up
 

Tango Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 06/17/2026 16:00
Tango Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,277.31 mln
Float69.56 mln
Earnings Date08/12/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-1.68
Likely manipulated

1-Year Forecast

40.45
Strong upside

Relative Strength

99 / 100
Top performer

Debt / Equity

0.08
Debt-free

ROE

-44.70
Deeply negative

Business Description

Tango Therapeutics is a Boston-based drug discovery company focused on developing targeted cancer treatments for patients with limited options. Its lead programs include two PRMT5 inhibitors currently in clinical trials for pancreatic, lung, and brain cancers, as well as a separate therapy designed to help the immune system recognize and attack lung tumors driven by a specific genetic mutation. Founded in 2017, the company builds its pipeline around matching treatments to the precise genetic profiles of cancer patients.

Key Fundamentals

EPS-0.83
ROE-44.70
RPS0.49
ROIC-198
ROA-34.44
EBITDA, mln-115
EV / EBITDA-21.47
EV / EBIT-21.08
Revenue, mln56.99
EV / Revenue43.48

Financial Strength

Altman Z-Score37.89
Piotroski F-Score 3 / 9
Beneish M-Score-1.68
1-Year Target Price40.45
Short Ratio11.02
Short % of Float23.46

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 12.59% 92 / 100   
1 Month 56.52% 98 / 100   
2 Months 90.05% 97 / 100   
6 Months 254% 99 / 100   
1 Year 574% 99 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us